Metabolic Research

Retatrutide

GIP / GLP-1 / glucagon triple agonist

Also known as LY3437943, GGG tri-agonist.

A single-peptide agonist of the GIP, GLP-1 and glucagon receptors (LY3437943), used in incretin-receptor pharmacology and metabolic-model research.

Current lot: SN-RET-2608
Purity: 99.31% by HPLC
Tested: Aug 22, 2026
Stocked in: United States, Canada, Australia

Synamino Sciences research vial with a silver cap on a navy background

Ships from

Vial size

$79.00

USD · 10 mg · In stock

Qty

Order by 2:00 PM PT for same-day dispatch from Reno, Nevada. 1–3 business days by USPS Priority and UPS. Free shipping over $150.00.

For laboratory research use only. Not for human or veterinary use.

About the compound

Retatrutide is a lipidated 39-residue peptide engineered to activate three receptors that regulate energy balance. It is the most requested triple agonist in receptor-signalling and body-composition research.

Supplied as a lyophilized powder in 10 mg and 20 mg vials.

Studied inIncretin receptors · Glucagon receptor · Energy balance models

Certificate of analysis

The certificate for the lot currently shipping. Every vial in that lot carries the same lot number on its label.

Certificate of analysis

Retatrutide · 10 mg

Lot SN-RET-2608 · tested Aug 22, 2026

99.31%

Purity by HPLC

Labeled: 10 mg
Measured: 10.3 mg
Panel: 6 passed · 2 reported
Laboratory: Independent ISO/IEC 17025 accredited laboratory

Assay	Method	Result	Outcome
Appearance	Visual	White lyophilized powder	Pass
Purity	HPLC · spec ≥ 98%	99.31%	Pass
Net peptide content	HPLC	10.3 mg	Reported
Identity	LC-MS	Confirmed	Pass
Heavy metals	ICP-MS	Not detected	Pass
Sterility	USP <71>	No growth	Pass
Endotoxin	LAL · USP <85>	< 0.05 EU/mL	Reported
Residual solvents	GC-HS	Within limits	Pass

Specification and storage

CAS number: 2381089-83-2
Molecular formula: C221H342N46O68
Molecular weight: 4731.3 g/mol
Residues: 39
Sequence: H-Tyr-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-(αMeLeu)-Leu-Asp-Lys-Lys(γGlu-AEEA-AEEA-C20 diacid)-Ala-Gln-Aib-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2
Reference record: PubChem entry

Storage

Sealed lyophilized vials are stable at room temperature for short periods; store at 2–8 °C for routine use.
For long-term storage keep sealed vials at −20 °C, protected from light and moisture.
Reconstituted solutions should be refrigerated at 2–8 °C and used within the period defined by your laboratory's protocol.

Literature

Peer-reviewed publications on this compound. Provided for reference; they are not claims about this product.

01
Lancet · 2022
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Urva S, Coskun T, Loh MT, et al.
02
The New England Journal of Medicine · 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
03
Lancet · 2023
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
Rosenstock J, Frias J, Jastreboff AM, et al.

Studied alongside

Tirzepatide
GIP / GLP-1 dual agonist
from $59.00
Cagrilintide
Long-acting amylin analogue
from $69.00
MOTS-c
Mitochondrial-derived peptide
from $42.00

Research notice

Retatrutide is supplied for in vitro laboratory research and analytical use by qualified professionals. It is not a medicine, supplement or cosmetic, has not been evaluated by any regulator, and is not for human or veterinary use. Published findings cited on this page are provided for reference and are not claims about this product.